FY 2024 Financial Management Plan

Share:

EmailFacebookLinkedInXWhatsAppShare

NIBIB FY24 paylines by grant mechanism are shown along with administrative budget reductions, if any. For all awards, no inflationary increases are provided in calculating future year's commitments.

GRANTS MECHANISMPERCENTILE PAYLINE (see notes below for superscripts)ADMINISTRATIVE BUDGET REDUCTION
R01 (Parent NOFO)16%1
  • 10% reduction for competing awards to Early-Stage Investigators (ESIs) and modular budgets
  • 24% reduction for competing awards to non-ESIs with non-modular budgets
  • Competing awards limited to four years
  • 2% reduction for non-competing awards
R21Select Pay2
  • 10% reduction for competing awards to the parent R21 NOFOs (PA-20-194 and PA-20-196)
  • All other R21s, no reduction
R03, R15Select Pay2
  • No reduction
P41Select Pay2
  • 10% reduction for competing awards applied to the first-year budget period ($500K equipment allowance excluded)
Bioengineering Partnerships with Industry U01sSelect Pay2
  • 15% reduction for competing awards to the BPI NOFO (PAR-22-123)
F32, F33, T32, K01, K08, K23, K24, K25, K99/R00, SBIR, STTRSelect Pay2No reduction
Expanded Opportunity Zone (EOZ)Select Pay3 Negotiated

Notes:

1 The percentile payline applies to R01 applications submitted to Parent Announcements. Other percentiled and non-percentiled R01 applications are select pay. The percentile payline for new investigator R01 applications submitted to Parent Announcements is 5% higher, i.e. 21%. See policy at New investigator Funding Policy. The percentile payline for ESIs is 13% higher, i.e., 29% for FY24 only. This is not a new permanent ESI policy at NIBIB.

No fixed payline exists. Applications are considered for funding on a case-by-case basis based on programmatic considerations and available funds.

3The NIBIB Expanded Opportunity Zone (EOZ) policy allows selected funding for some applications with percentile scores beyond the payline. Criteria are outlined at EOZ